Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELOVL6 | Q9H5J4 | 5/20 | 0.41 |
| ▸ | CTSS | P25774 | 7/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.37 |
| ▸ | CTSL | P07711 | 2/20 | 0.36 |
| ▸ | CTSB | P07858 | 2/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL694697 | 1.00 | ELOVL6 (0.41) | ELOVL6CTSSSMN1; SMN2TRPA1EPHX2 | |
| SCHEMBL695506 | 0.91 | ELOVL6 (0.43) | ELOVL6CTSSEPHX2PTGS2PTGS1 | |
| SCHEMBL695189 | 0.90 | CTSS (0.49) | ELOVL6CTSSSMN1; SMN2CTSLCTSB | |
| SCHEMBL2104910 | 0.90 | CTSS (0.49) | ELOVL6CTSSSMN1; SMN2CTSLCTSB | |
| SCHEMBL696422 | 0.89 | SMN1; SMN2 (0.41) | CTSSSMN1; SMN2TRPA1EPHX2PTGS2 | |
| SCHEMBL2105284 | 0.89 | SMN1; SMN2 (0.41) | CTSSSMN1; SMN2TRPA1EPHX2PTGS2 | |
| SCHEMBL696229 | 0.85 | CTSS (0.55) | CTSSCTSLCTSB | |
| SCHEMBL2105017 | 0.85 | CTSS (0.52) | CTSSSMN1; SMN2TRPA1CTSLCTSB | |
| SCHEMBL697407 | 0.85 | CTSS (0.52) | CTSSSMN1; SMN2TRPA1CTSLCTSB | |
| SCHEMBL2105671 | 0.84 | CRHR1 (0.39) | CTSSSMN1; SMN2TRPA1CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421826-B1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-8163793-B2 | Proline derivatives | HOFFMAN-LA ROCHE INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | PRAP1, PRR12, SLC6A7 | ELOVL6 2446/4885CTSS 1542/4885SMN1; SMN2 3026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.